The World Health Organization convenes an emergency meeting Monday to help determine its response to the Zika virus.
Developing a vaccine is no small feat. First, you need a lot of cash, said Dr. Ken Kaitin at the Tufts Center for the Study of Drug Development.
“It could take close to $1 billion to bring one successful compound to market,” he said.
Then, Kaitin said, given that pregnant women are at risk, that complicates the process for drug makers.
“In anything that’s dealing with pregnancy or children for that matter, you have an added obstacle because you don’t want to create a bigger problem then you are trying to cure,” he said.
A few of the biggest drug companies in the world are exploring vaccine development, including GlaxoSmithKline and Sanofi.
The Zika virus could infect some 4 million people in the Americas, and that’s why Sanofi’s Dr. Paul Beninger hopes U.S. health officials round up all the pharmaceutical executives and put the screws to them.
“Putting the finger to every person in the room and say I need your help to do this. And I think people respond to that. It’s when they aren’t identified it doesn’t happen,” he said.
Beninger said as we saw with Ebola, the capacity to develop a vaccine is there. It’s just a question of unlocking it.
“I think the best compliment I can give is not to say how much your programs have taught me (a ton), but how much Marketplace has motivated me to go out and teach myself.” – Michael in Arlington, VABEFORE YOU GO